‹ go back

5th October 2013 - The CE Mark allows the system to be sold throughout the European Union

SensiumVitals® receives CE marking; first UK hospital pilot

Toumaz Limited (AIM: TMZ, ‘Toumaz’, or ‘the Group’), a pioneer in low-power wireless semiconductor and software technologies, announces that SensiumVitals®, its ultra-low power system for wireless monitoring of patient vital signs, has received CE marking under the EU Medical Devices Directive.

 

The CE Mark allows the system to be sold throughout the European Union, and follows the product’s US FDA 510k clearance, received in July 2011.

The Group has also secured the first UK pilot deployment of SensiumVitals® with Spire Healthcare (‘Spire’), a leading UK provider of private healthcare.

 

The pilot will start in a Spire Healthcare hospital in early 2014. Spire has 38 hospitals across the country and has earned a reputation as a leader in patient care.

A similar pilot, conducted earlier this year in the med-surgical unit at Saint John’s Health Center, Santa Monica, California, provided clear evidence of both the clinical and economic benefits of the system (see www.toumaz.com/sensiumvitals®-pilot-study).

Separately, Toumaz has also announced today a new distribution agreement with NantHealth for SensiumVitals® in North America, including its first commercial order and confirmation of its first  pilot deployment in an A&E department at Hurley Medical Center, Flint, Michigan (see separate release).

Anthony Sethill, CEO of Toumaz, said:

 

“The CE mark and first UK pilot deployment of SensiumVitals® are key milestones for Toumaz Healthcare and we are extremely excited to be working with Spire Healthcare, a leading innovator in healthcare provision. 

 

”Results from the SensiumVitals® pilot in North America have provided clear evidence that the system can shorten hospital stays and reduce healthcare costs. We are confident that similar results will be achieved in the UK and the rest of Europe. This pilot is the first step in demonstrating that SensiumVitals® can be a key component of the UK Government’s strategy to use technology to deliver cost-effective improvements in patient care.” 

 

Dr Jean-Jacques de Gorter, Clinical Director of Spire Healthcare, said:

 

“Spire Healthcare aims to provide the highest possible standard of care to patients, and we are continually seeking to take advantage of the latest medical technology to help make care even safer for patients and to deliver a first class patient experience

 

“SensiumVitals® will enable clinicians to capture patient deterioration at a very early stage, allowing more rapid intervention and better patient outcomes. We are delighted to be the first hospital in the UK to evaluate this cutting edge medical technology.”

 

Enquiries:

Toumaz Limited

+44 (0)20 7391 0630

Anthony Sethill, Chief Executive Officer

 

Jonathan Apps, Chief Financial Officer

 

 

 

Peel Hunt LLP (Nominated Adviser and Broker)

+44 (0)20 7418 8900

Richard Kauffer/Daniel Harris

 

Vijay Barathan (Healthcare & Life Sciences)

 

 

 

College Hill

+44 (0)20 7457 2056

Adrian Duffield/Rozi Morris

 

About Toumaz (www.toumaz.com)

Toumaz Limited is a pioneer in low-power, wireless semiconductor and software technologies for healthcare and consumer audio. The company has two divisions, Toumaz Healthcare and Frontier Silicon. Toumaz Healthcare develops wireless solutions for patient monitoring. Frontier Silicon provides chip, modules and software for digital radio and connected audio devices.

About SensiumVitals®

SensiumVitals® is an ultra-low power system for wireless monitoring of patient vital signs, including heart rate, temperature and respiration.  Measurements are taken every two minutes, rather than every four to eight hours, as is currently standard in general wards. Patient data is then sent wirelessly and securely to clinicians via hospital IT systems.

The key benefit of SensiumVitals® is that it provides clinicians with rapid warnings of patient deterioration, which in turn allows for earlier interventions, and the potential for improved patient care and shorter stays in hospital.

 

‹ go back